Sunshine Biopharma Inc.

Sunshine Biopharma Inc. has filed an S-1 registration statement for an offering of up to 10,180,337 common units, each consisting of one share of common stock and two Series D Warrants. The company is also offering pre-funded units as an alternative for certain investors. The offering is being conducted on a best efforts basis with Aegis Capital Corp. acting as the exclusive placement agent. The company anticipates raising approximately $6.0 million in net proceeds, which will be used for general corporate purposes, including working capital. The common stock is listed on Nasdaq under the symbol SBFM.

Sunshine Biopharma Inc. reported a Q2 2026 revenue of $9.26 million, a slight decrease from $9.41 million in Q2 2025. The company's net loss for the quarter improved to $(1.56) million from $(1.77) million year-over-year, with basic loss per share improving to $(1.15) from $(3.94). For the six months ended June 30, 2026, the company raised $7.80 million from financing activities, significantly boosting its cash and cash equivalents to $13.75 million. The company also settled a legal dispute for $1.06 million and initiated an At-The-Market offering to raise additional capital.

Sunshine Biopharma Inc. announced that the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. This adjustment is a result of recent sales of the company's common stock under its previously disclosed at-the-market offering. The exercise price remains subject to further adjustments as outlined in the Series B Warrants.

Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. on July 20, 2026. This agreement allows the company to sell shares of its common stock for an aggregate offering price of up to $4,000,000 through Aegis Capital Corp. as its exclusive sales agent. Aegis Capital Corp. will receive a 3.0% commission on the gross proceeds from any shares sold under the agreement.

Sunshine Biopharma Inc. and its wholly-owned subsidiary, Nora Pharma Inc., have entered into a Release Agreement with Malek Chamoun, the former president of Nora Pharma. This agreement resolves a dispute between the parties, with Sunshine Biopharma agreeing to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement. The settlement also releases Mr. Chamoun from his non-competition and non-solicitation obligations.

Sunshine Biopharma Inc. announced the closing of its public offering on May 19, 2026, raising approximately $6 million in gross proceeds. The offering consisted of Common Units and Pre-Funded Units, each including shares or pre-funded warrants and two Series C warrants. Aegis Capital Corp. acted as the exclusive placement agent, receiving a 7% fee and a 2% expense allowance. The company anticipates using the net proceeds for general corporate purposes and working capital, with a potential for an additional $12 million if all Series C warrants are fully exercised.

Sunshine Biopharma Inc. reported a Q1 2026 net loss of $1.24 million, widening from $1.18 million in Q1 2025, with sales decreasing by 9.1% to $8.09 million. The company is engaged in a legal dispute over a $5.3 million earnout with a former subsidiary president. Despite financial challenges, the company is advancing its K1.1 mRNA liver cancer drug, which showed positive initial results in animal testing, and plans to launch 12 new generic drugs in 2026.

Sunshine Biopharma Inc. filed an S-1 registration statement for a public offering of up to $6,000,000 in common units and pre-funded units. Each common unit consists of one share of common stock and two Series C Warrants, while pre-funded units include a pre-funded warrant and two Series C Warrants. The company expects to receive approximately $5.0 million in net proceeds, which will be used for general corporate purposes, including working capital. The offering is on a best efforts basis with no minimum amount required to close, and involves significant dilution for existing shareholders.

Sunshine Biopharma Inc. announced its financial results for the fiscal year ended December 31, 2025, reporting total revenue of $36.3 million. This represents a 4.1% increase compared to the prior year, indicating continued top-line growth for the pharmaceutical company. The company focuses on developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, and this revenue growth suggests progress in its commercialization or development efforts.